Header cover image

South Korean (KOSPI) Biotech Industry Analysis

UpdatedJul 03, 2022
DataAggregated Company Financials
Companies93
  • 7D-2.1%
  • 3M-16.4%
  • 1Y-43.2%
  • YTD-32.9%

Over the last 7 days, the Biotech industry has risen 6.4%, driven by gains from Celltrion of 11%. During this same period, the Kainos Medicine underperformed, falling 80%. In the past year, the industry is down 41%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the South Korean Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Mon, 04 Jul 2022₩62.3t₩10.7t₩597.6b22.4x
Wed, 01 Jun 2022₩69.0t₩10.6t₩680.3b27.8x
Fri, 29 Apr 2022₩71.0t₩10.0t₩866.3b26.7x
Sun, 27 Mar 2022₩75.8t₩9.9t₩883.7b33.3x
Tue, 22 Feb 2022₩72.4t₩9.4t₩783.3b34.1x
Thu, 20 Jan 2022₩79.1t₩9.4t₩787.4b34.4x
Sat, 18 Dec 2021₩97.7t₩9.4t₩780.1b40.8x
Mon, 15 Nov 2021₩94.1t₩9.2t₩986.1b32.9x
Wed, 13 Oct 2021₩94.8t₩9.2t₩986.0b36.2x
Fri, 10 Sep 2021₩116.5t₩9.3t₩946.2b43.2x
Sun, 08 Aug 2021₩114.8t₩9.3t₩909.7b52.6x
Sat, 01 May 2021₩101.2t₩9.0t₩979.0b41.7x
Tue, 02 Feb 2021₩96.7t₩8.2t₩501.3b49.6x
Fri, 06 Nov 2020₩80.0t₩7.5t₩291.2b32.5x
Mon, 10 Aug 2020₩87.9t₩6.7t-₩13,176,736,074.0049.2x
Sun, 03 May 2020₩57.2t₩6.1t-₩304,564,934,452.0043.6x
Wed, 05 Feb 2020₩46.7t₩5.8t-₩212,594,028,191.0041.2x
Sat, 09 Nov 2019₩51.3t₩5.5t₩44.0b37.8x
Fri, 02 Aug 2019₩49.7t₩5.4t₩112.2b40.4x
Median PE Ratio

40.4x


Total Market Cap: ₩49.7tTotal Earnings: ₩112.2bTotal Revenue: ₩5.4tTotal Market Cap vs Earnings and Revenue0%0%0%
South Korean Biotech Industry Median PE3Y Average 40.8x202020212022
Current Industry PE
  • Investors are optimistic on the industry, and appear confident in long-term growth rates.
  • The industry is trading at a PE ratio of 107x which is higher than its 3-year average PE of -398x.
  • The industry's 3-year average PS ratio 10.1x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have grown 75% per year over the last three years.
  • Revenues for these companies have grown 25% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does South Korean Biotech compare with similar industries?

KR Market-2.64%
Healthcare-2.76%
Biotech-2.12%
Biotech-2.12%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A068270 Celltrion₩179.00k4.4%
+₩1.0t
-31.4%PE49.3x
A115450 HLB TherapeuticsLtd₩13.75k6.6%
+₩26.4b
17.0%PS9.1x
A086820 Bio SolutionLtd₩13.65k13.8%
+₩13.2b
-56.7%PS13.2x
A365270 Curacle₩17.70k5.0%
+₩11.7b
n/aPS35.7x
A235980 MedPacto₩22.95k2.2%
+₩10.7b
-67.8%PB8x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News